Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity

Vaccine

Volumn 33, Issue S2, 2015, Pages B55-B59

  Alter, Galit ^a   Sekaly, Rafick Pierre ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Adjuvants; Inflammation; Vaccine

Indexed keywords

ADJUVANT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; VACCINE; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; DENDRITIC CELL; HUMAN; IMMUNITY; INFLAMMATION; MICROBIOME; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL; IMMUNOLOGY; INNATE IMMUNITY;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; INFLAMMATION; VACCINES;

EID: 84929903543     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.058     Document Type: Review

References (46)

1. Hilleman M.R. A forward look at viral vaccines: with special reference to a new immunologic adjuvant. Am Rev Respir Dis 1964, 90:683-706.
2. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503. 10.1016/j.immuni.2010.10.002.
3. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86:973-983.
4. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397. 10.1038/41131.
5. Medzhitov R., Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91:295-298.
6. O'Hagan D.T., Ott G.S., Nest G.V., Rappuoli R., Giudice G.D. The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 2013, 12:13-30. 10.1586/erv.12.140.
7. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32. 10.1016/j.it.2008.09.006.
8. Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat Med 2013, 19:1597-1608. 10.1038/nm.3409.
9. Wu T.Y., et al. Rational design of small molecules as vaccine adjuvants. Sci Transl Med 2014, 6:263ra160. 10.1126/scitranslmed.3009980.
10. Liu H., et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014, 507:519-522. 10.1038/nature12978.
11. Brito L.A., O'Hagan D.T. Designing and building the next generation of improved vaccine adjuvants. J Controll Release 2014, 190:563-579. (official journal of the Controlled Release Society). 10.1016/j.jconrel.2014.06.027.
12. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239:178-196. 10.1111/j.1600-065X.2010.00978.x.
13. Kumar P., Chen K., Kolls J.K. Th17 cell based vaccines in mucosal immunity. Curr Opin Immunol 2013, 25:373-380. 10.1016/j.coi.2013.03.011.
14. Radstake T.R., van Lieshout A.W., van Riel P.L., van den Berg W.B., Adema G.J. Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis. Ann Rheum Dis 2005, 64:1532-1538. 10.1136/ard.2004.033779.
15. Medvedev A.E., Sabroe I., Hasday J.D., Vogel S.N. Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J Endotoxin Res 2006, 12:133-150. 10.1179/096805106X102255.
16. Chen J.Q., Szodoray P., Zeher M. Toll-like receptor pathways in autoimmune diseases. Clin Rev Allergy Immunol 2015, 10.1007/s12016-015-8473-z.
17. Marabelle A., Kohrt H., Caux C., Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014, 20:1747-1756. 10.1158/1078-0432.CCR-13-2116.
18. Panda A., et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010, 184:2518-2527. 10.4049/jimmunol.0901022.
19. Dudani R., et al. Preexisting inflammation due to Mycobacterium bovis BCG infection differentially modulates T-cell priming against a replicating or nonreplicating immunogen. Infect Immun 2002, 70:1957-1964.
20. Muyanja E., et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest 2014, 124:3147-3158. 10.1172/JCI75429.
21. Emens L.A. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther 2012, 12:1597-1611. 10.1586/era.12.147.
22. Siebert S., Tsoukas A., Robertson J., McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev 2015, 67:280-309. 10.1124/pr.114.009639.
23. Brooks D.G., Lee A.M., Elsaesser H., McGavern D.B., Oldstone M.B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med 2008, 205:533-541. 10.1084/jem.20071948.
24. Nguyen L.T., Ohashi P.S. Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol 2015, 15:45-56. 10.1038/nri3790.
25. Pandey M., Mahadevan D. Monoclonal antibodies as therapeutics in human malignancies. Future Oncol 2014, 10:609-636. 10.2217/fon.13.197.
26. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454. 10.1056/NEJMoa1200690.
27. Yao S., Zhu Y., Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nature reviews. Drug Discovery 2013, 12:130-146. 10.1038/nrd3877.
28. Crook K.R., Liu P. Role of myeloid-derived suppressor cells in autoimmune disease. World J Immunol 2014, 4:26-33. 10.5411/wji.v4.i1.26.
29. Botta C., Gulla A., Correale P., Tagliaferri P., Tassone P. Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol 2014, 4:348. 10.3389/fonc.2014.00348.
30. Kong Y.Y., Fuchsberger M., Xiang S.D., Apostolopoulos V., Plebanski M. Myeloid derived suppressor cells and their role in diseases. Curr Med Chem 2013, 20:1437-1444.
31. Fernandez A., et al. Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum Vaccines Immunother 2014, 10:3251-3260. 10.4161/hv.29847.
32. Sampson J.H., et al. A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS ONE 2012, 7:e31046. 10.1371/journal.pone.0031046.
33. Matsushita N., Pilon-Thomas S.A., Martin L.M., Riker A.I. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008, 333:167-179. 10.1016/j.jim.2008.01.012.
34. Srivastava M.K., et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE 2012, 7:e40677. 10.1371/journal.pone.0040677.
35. Khattri S., Zandman-Goddard G. Statins and autoimmunity. Immunol Res 2013, 56:348-357. 10.1007/s12026-013-8409-8.
36. Knowler W.C., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. 10.1056/NEJMoa012512.
37. Forero-Pena D.A., Gutierrez F.R. Statins as modulators of regulatory T-cell biology. Mediat Inflamm 2013, 2013:167086. 10.1155/2013/167086.
38. Kou J., et al. Combined treatment of Abeta immunization with statin in a mouse model of Alzheimer's disease. J Neuroimmunol 2012, 244:70-83. 10.1016/j.jneuroim.2012.01.008.
39. Ravindran R., et al. Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation. Science 2014, 343:313-317. 10.1126/science.1246829.
40. Araki K., Ellebedy A.H., Ahmed R. TOR in the immune system. Curr Opin Cell Biol 2011, 23:707-715. 10.1016/j.ceb.2011.08.006.
41. Mannick J.B., et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014, 6:268ra179. 10.1126/scitranslmed.3009892.
42. Oh J.Z., et al. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity 2014, 41:478-492. 10.1016/j.immuni.2014.08.009.
43. Pabst O., Hornef M. Gut microbiota: a natural adjuvant for vaccination. Immunity 2014, 41:349-351. 10.1016/j.immuni.2014.09.002.
44. Akatsu H., et al. Enhanced vaccination effect against influenza by prebiotics in elderly patients receiving enteral nutrition. Geriatr Gerontol Int 2015, 10.1111/ggi.12454.
45. Valdez Y., Brown E.M., Finlay B.B. Influence of the microbiota on vaccine effectiveness. Trends Immunol 2014, 35:526-537. 10.1016/j.it.2014.07.003.
46. Honda K., Littman D.R. The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012, 30:759-795. 10.1146/annurev-immunol-020711-074937.